ArticleEuropean journal of nuclear medicine and molecular imaging2025
Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeuroendocrine neoplasms (NENs) represent a rare group of neoplasms originating from neuroendocrine cells in almost any part of the body. One of subsequent line of treatment is radioligand therapy (RLT) with use of beta-emitting isotopes. The most common adverse events are deterioration of kidney and bone marrow function. The aim of the study was to assess the differences in complications and outcomes of RLT between patients with initially low and normal renal function.
methodsStudy group included 127 patients with progressive NENs who underwent one cycle of RLT. Renal, bone marrow, glucose, and chromogranin A were assessed before Course I, Course IV and in follow-up. A representative subgroup of 44 patients reported for long-term visit.
resultsRLT did not cause significant decrease of GFR during the treatment, however over 6% GFR decrease was observed in long-term follow-up. Blood morphology parameters significantly decreased during the treatment, and remained decreased in long-term observation. Glucose concentration did not change during the treatment, though an increase of 12 mg/dL in long-term observation was noted. Patients with initially lower GFR had improvement in GFR values. Calculated PFS and OS probability at 60 months after treatment were 41.5% and 74% respectively.
conclusionsRLT cause a statistically but not clinically significant decrease of all blood morphology parameters. In long-term observation after RLT a decrease of GFR and increase in glucose concentration are observed. Initially low GFR seems not to limit the possibility of RLT, and even GFR increase in this group of patients is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.